ANNOUNCEMENT

Listing of additional shares of iDNA Genomics Public Ltd

(Emerging Companies Market)

The Cyprus Stock Exchange announces that it has admitted for trading on the Cyprus Stock Exchange, pursuant to Article 58(1) of the CSE Law, 160,333 ordinary shares of the company "iDNA Genomics Public Ltd", which have been issued and allotted with the method of private placement to Mr. Fotis Sakellarides, for a consideration in specie of 5% of the issued share capital of TheraCell Advanced Biotechnology S.A. of an estimated value of €3,848,004, i.e. with a price per share at €24, and with their simultaneous registration to the Central Securities Depository and Central Registry of the CSE pursuant to Articles 10(1) and (3) of the Securities and Cyprus Stock Exchange (Central Securities Depository and Central Registry) Law.

It is noted that the above shares will be incorporated into the company's already listed share capital, which will increase to 2,760,333 shares.

The trading of the shares will commence on Wednesday, 15 February 2023.

Nicosia, 10 February 2023

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

iDNA Genomics Public Ltd. published this content on 10 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 February 2023 06:35:03 UTC.